



PTO/SB/21 (08/03)

Approved for use through 07/31/2006. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)		Application Number	10/066,782
		Filing Date	February 6, 2002
		First Named Inventor	Gary L. Griffiths et al.
		Art Unit	1617
		Examiner Name	SHARAREH, Shahnam J.
Total Number of Pages in This Submission		Attorney Docket No.	40923-0077 US2 (018733-1089) IMM 136

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 (CFR) 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s), please identify below: Response to Restriction Requirement
Remarks CUSTOMER NO. 26633		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual Name	Paul M. Booth, Reg. No. 40,244, HELLER EHRMAN LLP
Signature	
Date	February 13, 2006

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Typed or printed name			
Signature		Date	

This collection of information is required by 37 C.F.R. 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 C.F.R. 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions by reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

IFW



Attorney Docket No.: 40923-0077 US2
(Previous Docket No.: 018733-1089)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of:
Gary L. Griffiths *et al.*

Confirmation No.: 5555

Application No.: 10/066,782

Art Unit: 1617

Filed: 6 February 2002

Examiner: SHARAREH, Shahnam J.

For: **METHODS AND COMPOSITIONS FOR INCREASING THE TARGET-SPECIFIC TOXICITY OF A CHEMOTHERAPY DRUG**

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This responds to the Restriction Requirement mailed January 11, 2006, a response to which is due February 11, 2006. Applicants do not believe that any additional fees are needed. In the event this is not correct, the Commissioner is authorized to charge the undersigned's account number 08-1641.

Applicants hereby elect the invention of Group I, claims 1-14 and 48, drawn to methods of increasing the target-specific toxicity of a drug. This election is made with traverse because the claims of Group II already have been searched and examined and including these claims will not pose a burden on the Examiner. Applicants note that claims 20-47 already were deemed allowable (subject to filing a terminal disclaimer) and therefore query as to why a restriction requirement is imposed here. In addition, the office action indicates that examination on the merits has been reopened on the basis of specific prior art. It would not impose a burden on the Examiner to apply this newly identified art to the claims of Group II. Accordingly, withdrawal of the restriction requirement is requested.

The Examiner also has imposed an election of species for initial examination on the merits. Applicants elect the species of:

Pretargeting agent: the bispecific antibody hMN14 IgG x 734 Fab';

Cytotoxic drug or prodrug: CPT-11;

Enzyme: combination of carboxylesterase and glucuronidase;

Clearing agent: Galactosylated version anti-idiotypic antibody, WI2, (gal-WI2).

Applicants note that, with respect to the enzyme, a combination of enzymes has been elected.. This species is described in, for example, Examples 5-7 of the application .

Claims 1-13 and 20-46 read on the elected species.

Applicants reserve the right to file one or more divisional applications directed to non-elected subject matter.

Applicants await issuance of an office action on the merits.

Respectfully submitted,



Paul M. Booth
Reg. No.: 40,244

Date: February 13, 2006

Heller Ehrman LLP
1717 Rhode Island Avenue, NW
Washington, D.C. 20036-3001
Telephone: (202) 912-2000
Facsimile: (202) 912-2020

Customer No. 26633